AXSM · Axsome Therapeutics Inc
Price
Snapshot
50 fields · last close| Market Cap | $8.23B |
| P/E | — |
| Float | 43.19M |
| Beta | 0.82 |
| Volatility | 20.5% |
| Exchange | NASDAQ |
| Sector | Pharmaceuticals |
| Cap tier | Mid cap |
| Macro sensitivity | Moderate |
| Clavix score | 73.5 |
| Price | 156.29 |
| Change | −0.54% |
| Prev Close | 157.14 |
| Open | 160.43 |
| Day Low | 156.09 |
| Day High | 160.43 |
| Avg Vol | 1 |
| Avg $ Vol | $151.5M |
| 52W High | 260.19 |
| 52W Low | 123.50 |
| 52W Pos | 24.0% |
| From High | −39.93% |
| From Low | +26.55% |
| Max DD 1Y | −38.74% |
| Spread | 0.10% |
| Liquidity | Normal |
| SMA 20 | −12.81% |
| SMA 50 | −21.04% |
| SMA 200 | −22.08% |
| RSI (14) | 24.0 |
| Vol 30D | 39.5% |
| Vol 90D | 38.4% |
| 1Y Range | 124–260 |
| Daily bars | 900 |
| Perf Week | −6.66% |
| Perf Month | −26.67% |
| Perf Quarter | −29.10% |
| Perf Half Y | −16.85% |
| Perf Year | +21.27% |
| Perf YTD | −12.54% |
| Prev Day | −0.54% |
| Clavix | B |
| Debt / Eq | 3.25 |
| Curr Ratio | 1.55 |
| Int Cover | -37.1× |
| FCF Margin | −14.7% |
| Rev Growth | +65.5% |
| Profit | Unprofitable |
| Leverage | Very High |
| Sector rank | 11 / 14 |
Clavix risk grade
regraded every trading dayAXSM grades B, 73.5 of 100. Steadiest on Macro Resilience (62), most exposed on Price Stability (57, mixed). 0 of the 3 weighted dimensions sit above the Pharmaceuticals median. Ranks 11 of 14 in Pharmaceuticals by Clavix score.
How rough the ride is
| AXSM | Pharmaceuticals median | |
|---|---|---|
| Betavs the overall market · lower is steadier | 0.82 | 0.44 |
| Volatilityannualized | 20.5% | 10.9% |
| Max drawdown, past yearworst peak-to-trough fall | −38.7% | — |
| Typical daily movemedian absolute daily change | 1.26% | — |
| Days beyond ±3%of the last 252 sessions | 47 (19%) | — |
How its days are spread
Daily returns over the last 252 sessions in 1% bins. Moves beyond ±6% land in the end bins.
52-week range
The bar runs from the lowest to the highest close of the last 252 sessions; the marker is the latest close.
Drawdown from the 1-year peak
Percent below the running high over the last 12 months. Zero is a fresh high.
Market sensitivity
| AXSM | Pharmaceuticals median | |
|---|---|---|
| Beta to the markethow much it swings with the S&P 500 · lower is safer | 0.82 | 0.44 |
| Macro sensitivityrate, dollar and credit exposure bucket | Moderate | Low 67% of 15 |
Where it sits on the macro scale
Low means rates, the dollar and credit spreads barely move it. Very High means they drive a large share of its swings. The counts are how many Pharmaceuticals names sit in each bucket.
Where it ranks in its sector
Rank by Clavix score within the sector. Right is the top of the sector.
Price performance
| AXSM | |
|---|---|
| 1 week | −6.7% |
| 1 month | −26.7% |
| Year to date | −12.5% |
| 1 year | +21.3% |
Context for the rank, not itself a risk measure.
Recent coverage, scored
| AXSM | |
|---|---|
| Articles scoredthe most recent scored coverage, up to 30 | 30 since 8 Jul |
| Average score0 most bearish, 100 most bullish | 60 |
| Bullish · bearisharticles above 60 · below 40 | 19 · 6 |
| Directionarticles whose tone is improving vs worsening | 19 ↑ 6 ↓ |
Where the article scores land
Each bar is a 10-point band of article scores. Below 40 reads bearish, above 60 bullish.
Balance sheet, against the sector
The shaded band is the middle half of the 15 Pharmaceuticals names Clavix covers; the tick is the sector median.
Growth
| AXSM | |
|---|---|
| Revenue growthyear over year | +65.5% |
Financial Health is shown but does not count toward the grade. Why
0–100, higher is safer. The tick on each bar is the Pharmaceuticals median. Click a dimension for the evidence behind it. Financial Health is shown but does not count toward the grade.
Recent news
most recent scored articles · the chip is the article’s score · click to openAxsome Therapeutics announced results from the 'Shared Goals: Navigating Alzheimer's Agitation' survey of caregivers, finding that 97% of care partners reported agitation symptoms negatively impacted their loved one's quality of life and three in four wished they had recognized symptoms sooner.
Axsome Therapeutics executives said prescriptions for its drug AUVELITY are growing faster, helped by a recent expansion of its sales team and the launch of the drug for treating agitation in Alzheimer's disease. Management also expects operating expenses to stay roughly steady in the second half of the year.
Axsome Therapeutics said prescriptions for its drug AUVELITY are growing faster following a recent expansion of its sales team and the launch of the drug to treat agitation in Alzheimer's disease. Management also indicated that operating expenses are expected to stay roughly steady.
Axsome Therapeutics presented new clinical trial results for major depressive disorder and Alzheimer's disease agitation at the Psych Congress 2026 conference in New Orleans, including data on its dextromethorphan-bupropion treatment.
Axsome Therapeutics executives discussed growth in its commercial portfolio, an expanded sales force, and several late-stage clinical programs at the H.C. Wainwright investment conference.
Nearest peers by size
Pharmaceuticals| Ticker | Company | Grade | Mkt cap | P/E | Beta | |
|---|---|---|---|---|---|---|
| CRNX | Crinetics Pharmaceuticals Inc | — | $9.01B | — | 0.45 | Compare |
| ELAN | Elanco Animal Health Inc | B | $11.77B | — | 1.74 | Compare |
| CORT | Corcept Therapeutics Inc | C | $11.91B | 215.80 | 0.52 | Compare |
| JAZZ | Jazz Pharmaceuticals PLC | A- | $13.65B | 14.51 | 0.38 | Compare |
| MANE | Veradermics Inc | C+ | $4.55B | — | 0.44 | Compare |
| VTRS | Viatris Inc | B+ | $21.43B | — | 0.89 | Compare |
| ZTS | Zoetis Inc | B+ | $31.87B | 12.55 | 0.70 | Compare |
| RPRX | Royalty Pharma PLC | A | $35.06B | 43.01 | 0.39 | Compare |
You just read one holding. Clavix reads the whole portfolio.
Every position you own, graded on the same five dimensions, with an alert when a grade moves. 1 month free on iPhone.